In its second largest business acquisition to date, Boston Scientific has acquired UK medical device company BTG plc in a deal worth potentially £3.3 B (US$4.2 B). The deal gives Boston Scientific a range of minimally invasive therapies including BTG’s TheraSphere radiotherapy microspheres and the EKOS Endovascular System, which will strengthen the company’s presence in interventional oncology and vascular devices. News of the takeover comes less than a week after Boston Scientific revealed plans to reduce operational costs by US$150 M by 2022.